



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

11 November 2021  
EMA/CHMP/603118/2021  
Committee for Medicinal Products for Human Use (CHMP)

## Summary of opinion<sup>1</sup> (post authorisation)

---

### Epclusa

sofosbuvir / velpatasvir

On 11 November 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Epclusa. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC.

The CHMP adopted an extension to the indication for Epclusa as follows:<sup>2</sup>

Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients ~~aged 67~~ **aged 3 years of age** and older ~~and weighing at least 17 kg~~.

The CHMP also recommended the addition of a new pharmaceutical form as follows: 150/37.5 mg coated granules in sachet and 200/50 mg coated granules in sachet.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

---

<sup>1</sup> Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

<sup>2</sup> New text in bold, removed text as strikethrough.

